Icon PLC (ICLR) Up 2.5% Since Last Earnings Report: Can It Continue?
Icon PLC (ICLR) reported earnings 30 days ago. What's next for the stock?
ICLR - ICON Public Limited Company
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$170.64
DETAILS
HIGH:
$207.00
LOW:
$105.00
MEDIAN:
$175.00
CONSENSUS:
$170.64
UPSIDE:
3.51%
Stock News
A Look at Icon PLC (ICLR) After 3.2% Gain -- GF Value $208.22 vs Price $172.49
On August 19, 2026, Icon PLC (ICLR) shares rose 3.2% today, closing at $172.49, which is within its 52-week range of $66.57 to $203.91. This recent uptick in sh
Icon PLC (ICLR) Shares Surge 3.9% -- What GF Score of 93 Tells Investors
On August 17, 2026, Icon PLC (ICLR) shares rose 3.9%, bringing the current price to $169.45. This price is situated within a 52-week range of $66.57 to $203.91,
Oakmark Concentrated Strategy Q2 2026 Performance Review
The portfolio's return was 9.21% (net) for the reporting period. Centene, ICON and Keurig Dr Pepper were the contributors during the quarter. Intercontinental Exchange, Salesforce and ConocoPhillips were the detractors during the quarter.
Is ICON a Buy as Valuation Improves but Earnings Risks Still Persist?
ICLR's discounted valuation and $23.4B backlog support upside potential, but falling estimates, weaker margins and execution risks argue for patience.
ICON Announces Pricing of USD 2.15 Billion Notes
DUBLIN--(BUSINESS WIRE)--ICON Announces Pricing of USD 2.15 Billion Notes.
ICLR Jumps 33.2% in Three Months as Recovery Expectations Strengthen
ICON's 33.2% rally is backed by stronger proposal flow, bookings and backlog, but weaker earnings and margins cloud the recovery.
ICON Announces Private Offering of Notes
DUBLIN--(BUSINESS WIRE)--ICON plc (NASDAQ: ICLR) (“ICON”), a world-leading clinical research organization, announced today that its wholly-owned subsidiary, ICON Investments Six Designated Activity Company (the “Issuer”), intends to offer one or more series of senior notes (the “Notes”), in a private offering (the “Offering”) with registration rights, subject to market and other conditions. The Notes will be guaranteed on a senior unsecured basis by ICON.
Icon Plc $ICLR Shares Sold by Avidity Partners Management LP
Avidity Partners Management LP lowered its stake in Icon Plc (NASDAQ: ICLR) by 51.7% during the undefined quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 16,000 shares of the medical research company's stock after selling 17,100 shares during the period. Icon makes up about 0.4%
ICON Announces Results of Annual General Meeting
DUBLIN--(BUSINESS WIRE)--ICON Announces Results of Annual General Meeting.
ICON Public Limited Company (ICLR) Q2 2026 Earnings Call Transcript
ICON Public Limited Company (ICLR) Q2 2026 Earnings Call Transcript
Icon Q2 Earnings Call Highlights
Icon NASDAQ: ICLR reported second-quarter 2026 revenue growth and strong bookings as higher pass-through activity supported the top line, while the company continued to manage business-mix pressures affecting reported margins.
Icon PLC (ICLR) Lags Q2 Earnings Estimates
Icon PLC (ICLR) came out with quarterly earnings of $2.56 per share, missing the Zacks Consensus Estimate of $2.57 per share. This compares to earnings of $3.26 per share a year ago.
ICON Reports Second Quarter 2026 Results
DUBLIN--(BUSINESS WIRE)--ICON plc (NASDAQ: ICLR), a world-leading clinical research organization, today reported its financial results for the second quarter ended June 30, 2026.
ICON announces multi-year collaboration with Anthropic to bring frontier AI to clinical trials
DUBLIN--(BUSINESS WIRE)--ICON plc (NASDAQ: ICLR) today announced a multi-year collaboration with Anthropic to bring Claude's AI capabilities across the clinical trial lifecycle. The collaboration further advances ICON's digital innovation and AI strategy, and builds on Orbis – ICON's secure, governed, agentic AI platform. Through this collaboration, ICON will work closely with Anthropic's Life Sciences research team to explore and apply cutting-edge technologies that can accelerate innovation a.
Icon PLC (ICLR) Up 5.8% Since Last Earnings Report: Can It Continue?
Icon PLC (ICLR) reported earnings 30 days ago. What's next for the stock?
ICON Schedules Second Quarter 2026 Earnings Conference Call
DUBLIN--(BUSINESS WIRE)--ICON Schedules Second Quarter 2026 Earnings Conference Call.
Icon (ICLR) to Release Earnings on Wednesday
Icon (NASDAQ: ICLR - Get Free Report) is expected to release its Q1 2026 results after the market closes on Wednesday, July 29th. Analysts expect the company to post earnings of $2.55 per share and revenue of $2.0043 billion for the quarter. Interested persons are encouraged to explore the company's upcoming Q1 2026 earning report page
AVTR vs. ICLR: Which Stock Should Value Investors Buy Now?
Investors interested in stocks from the Medical Services sector have probably already heard of Avantor, Inc. (AVTR) and Icon PLC (ICLR). But which of these two stocks is more attractive to value investors?
Earnings Preview: Icon PLC (ICLR) Q2 Earnings Expected to Decline
Icon PLC (ICLR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Price Targets
Icon price target raised to $194 from $192 at Baird
$194.00
(was $165.53)
Robert W. Baird
Truist Securities Upgrades ICON plc (ICLR) to Buy
$207.00
(was $172.99)
Jailendra Singh
·
Truist Financial
Icon price target raised to $190 from $180 at Mizuho
$190.00
(was $160.96)
Ann Hynes
·
Mizuho Securities
Icon price target raised to $187 from $160 at BMO Capital
$187.00
(was $164.49)
BMO Capital
Icon price target raised to $186 from $168 at Baird
$186.00
(was $158.17)
Eric Coldwell
·
Robert W. Baird
Icon upgraded to Outperform from Sector Perform at RBC Capital
$185.00
(was $158.17)
RBC Capital
Icon price target raised to $175 from $160 at Barclays
$175.00
(was $158.17)
Barclays
Icon price target raised to $160 from $150 at Barclays
$160.00
(was $142.67)
UBS
ICON plc (ICLR) PT Raised to $164 at TD Cowen; 'Investigation Overhang Removed'
$164.00
(was $133.61)
D.A. Davidson
Icon price target raised to $159 from $139 at Truist
$159.00
(was $136.45)
Truist Financial
Icon price target raised to $165 from $135 at Jefferies
$165.00
(was $135.47)
Jefferies
ICON plc (ICLR) PT Raised to $126 at RBC Capital
$126.00
(was $136.80)
Ryan Halstead
·
RBC Capital
Icon price target raised to $145 from $125 at Leerink
$145.00
(was $138.71)
Leerink Partners
ICON plc (ICLR) PT Raised to $105 at BofA Securities
$105.00
(was $113.85)
William Blair
Icon resumed with a Sector Perform at RBC Capital
$123.00
(was $116.38)
Ryan Halsted
·
RBC Capital
Icon price target raised to $125 from $105 at Leerink
$125.00
(was $112.85)
Michael Cherny
·
Leerink Partners
Icon upgraded to Buy from Hold at Jefferies
$135.00
(was $99.70)
David Windley
·
Jefferies
Icon downgraded to Neutral from Buy at Rothschild & Co Redburn
$100.00
(was $93.00)
Jamie Clark
·
Redburn Partners
Icon price target lowered to $119 from $217 at Baird
$119.00
(was $91.63)
Robert W. Baird
Icon price target lowered to $100 from $175 at BMO Capital
$100.00
(was $84.63)
Sean Dodge
·
BMO Capital